Graciela Moreno - Endocan Corp VP Director
| ENDO Stock | USD 0.0001 0.00 0.00% |
Insider
Graciela Moreno is VP Director of Endocan Corp
| Phone | 888 263 0490 |
| Web | https://www.omnicanna.com |
Similar Executives
| Showing other executives | INSIDER Age | ||
| J Starzecki | 5E Advanced Materials | N/A | |
| Jeffrey Morris | Graphene Manufacturing Group | N/A | |
| CPA CPA | 5E Advanced Materials | 39 | |
| Bobby Bran | Graphene Manufacturing Group | N/A | |
| MBA BEng | 5E Advanced Materials | 60 | |
| Dinakar Gnanamgari | 5E Advanced Materials | 41 | |
| BCom BProc | Graphene Manufacturing Group | 50 | |
| Roberto Bran | Graphene Manufacturing Group | N/A | |
| Deborah Appleton | Graphene Manufacturing Group | N/A | |
| ACSA BBus | 5E Advanced Materials | 47 | |
| Anjana Reddy | Graphene Manufacturing Group | N/A | |
| ACSA AGIA | 5E Advanced Materials | 39 | |
| Ashok Nanjundan | Graphene Manufacturing Group | N/A | |
| Tim Scheiwe | Graphene Manufacturing Group | N/A | |
| Craig Nicol | Graphene Manufacturing Group | 48 | |
| Chance Pipitone | 5E Advanced Materials | N/A | |
| George Fairchild | 5E Advanced Materials | 57 | |
| Sheena Ward | Graphene Manufacturing Group | N/A | |
| Chantel Jordan | 5E Advanced Materials | 43 | |
Endocan Corp Leadership Team
Elected by the shareholders, the Endocan Corp's board of directors comprises two types of representatives: Endocan Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Endocan. The board's role is to monitor Endocan Corp's management team and ensure that shareholders' interests are well served. Endocan Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Endocan Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alfredo DupetitBernardi, VP Director | ||
| Graciela Moreno, VP Director | ||
| Mario Lap, President of European Operations and Director | ||
| Raymond Dabney, Pres CEO | ||
| Robert Kane, CEO and President Acting CFO and Director | ||
| Wayne Howey, Head Services | ||
| C Tam, S Treasurer | ||
| Steven Garrett, Chief Key | ||
| Anthony Spring, Head Director |
Endocan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Endocan Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 1.87 M | |||
| Shares Outstanding | 67.89 M | |||
| Price To Earning | (0.09) X | |||
| Price To Book | 18.51 X | |||
| Net Income | (3.31 M) | |||
| Cash And Equivalents | 59 | |||
| Total Debt | 954.59 K | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (105.94 K) | |||
| Earnings Per Share | (0.12) X |
Pair Trading with Endocan Corp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Endocan Corp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Endocan Corp will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Endocan Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Endocan Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Endocan Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Endocan Corp to buy it.
The correlation of Endocan Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Endocan Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Endocan Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Endocan Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Endocan Pink Sheet
Endocan Corp financial ratios help investors to determine whether Endocan Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Endocan with respect to the benefits of owning Endocan Corp security.